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ABSTRACT 30 
Genome-wide association studies have revealed many loci contributing to 31 
the variation of complex traits, yet the majority of loci that contribute to the 32 
heritability of complex traits remain elusive. Large study populations with 33 
sufficient statistical power are required to detect the small effect sizes of 34 
the yet unidentified genetic variants. However, the analysis of huge 35 
cohorts, like UK Biobank, is challenging. Here we present an atlas of 36 
genetic associations for 118 non-binary and 660 binary traits of 452,264 UK 37 
Biobank participants of white descent. Results are compiled in a publicly 38 
accessible database that allows querying genome-wide association results 39 
for 9,113,133 genetic variants, as well as downloading whole GWAS 40 
summary statistics for over 30 million imputed genetic variants (>23 billion 41 
phenotype-genotype pairs). Our atlas of associations (GeneATLAS, 42 
http://geneatlas.roslin.ed.ac.uk) will help researchers to query UK Biobank 43 
results in an easy and uniform way without the need to incur in high 44 
computational costs.  45 
  46 
  47 
   
 
   
 
INTRODUCTION 48 
Most human traits are complex and influenced by the combined effect of large 49 
numbers of small genetic and environmental effects1. Genome-wide association 50 
studies (GWAS) have identified many genetic variants influencing many complex 51 
traits. The largest genetic effects were discovered with modest sample sizes, with 52 
researchers subsequently joining efforts to increase the size of the study cohorts, 53 
thus allowing them to identify much smaller genetic effects. The UK Biobank2, a 54 
large prospective epidemiological study comprising approximately 500,000 55 
deeply phenotyped individuals from the United Kingdom, has been genotyped 56 
using an array that comprises 847,441 genetic polymorphisms, with a view to 57 
identifying new genetic variants in a uniformly genotyped and phenotyped cohort 58 
of unprecedented size, both in terms of the number of samples and number of 59 
traits.  60 
The unprecedented size of this cohort has raised a number of analytical 61 
challenges3. First, storing, managing and analysing the circa 90 million genetic 62 
variants for around half a million individuals is, in itself, a substantial endeavour. 63 
Second, the collection of samples at this scale has brought up an analytical 64 
challenge, as the cohort is structured by familial relationships and ethnicity. For 65 
instance, many relatives were unintentionally collected in the cohort, and 66 
removing them from the analyses as traditionally done in GWAS would entail a 67 
substantial loss of statistical power. Third, although recent developments have 68 
reduced the computational costs4, fitting a Linear Mixed Model (LMM), the 69 
standard analytical technique to perform GWAS when there is population or 70 
familial structure, at this scale and for this number of traits, entails a 71 
computational burden which may be beyond the means of many research labs.  72 
The objective of the current study was to perform GWAS for 778 traits in UK 73 
Biobank, adjusting for the effect of relatedness to minimise the loss of statistical 74 
power whilst reducing false positives due to familial and population structure, in 75 
individuals of white ancestry and to make a searchable atlas of genetic 76 
associations in UK Biobank for the benefit of the research community. 77 
RESULTS 78 
Data overview  79 
   
 
   
 
In July 2017, the UK Biobank released genotyped data from circa 490,000 80 
individuals of largely white descent genotyped for 805,426 genetic variants. We 81 
performed GWASs for 660 binary traits and 118 non-binary traits, the latter 82 
including continuous traits and traits with multiple ordered categories 83 
(Supplementary Table 1). For each of these traits we fitted LMMs to test for 84 
association with 623,944 genotyped and 30,798,054 imputed genetic 85 
polymorphisms imputed using the Haplotype Reference Consortium5 as 86 
reference panel, as well as 310 imputed HLA alleles. All successfully tested 87 
polymorphisms are shown in the database (GeneATLAS, 88 
http://geneatlas.roslin.ed.ac.uk) or associated downloadable files to allow 89 
individual researchers to apply their own quality control thresholds. The summary 90 
results presented here are based on the quality controlled imputed 91 
polymorphisms (9,113,133 variants after filtering) of 452,264 individuals 92 
(Methods). 93 
 94 
The phenotypes selected comprise a mix of baseline measurements (e.g. height), 95 
self-reported traits at recruitment (e.g. self-reported depression), and Hospital 96 
Episode Statistics (i.e. data collected during hospital admissions) as well as 97 
cancer diagnoses from the appropriate UK Cancer Registry. Since UK Biobank 98 
is a recently stablished prospective cohort, we allowed for potential differences in 99 
statistical power among binary and non-binary traits by splitting the presentation 100 
of the data into non-binary and binary traits.  101 
 102 
To demonstrate the power of using large datasets (so called, Big Data), we first 103 
explored how the analysis of increasingly large sample sizes enable new 104 
discoveries, and reduce bias when estimating the effect sizes of GWAS hits (Fig. 105 
1 and Supplementary Note). Our results show that the number of GWAS hits 106 
increased linearly with the sample size with no sign of saturation, thus suggesting 107 
that increasing the size of cohorts like UK Biobank would continue to yield new 108 
discoveries. We also observed that the estimated allelic effects of GWAS hits 109 
obtained from decreasing sample sizes were generally larger, which is in 110 
agreement with a Winner’s Curse effect6 (Fig. 1).  111 
 112 
Distribution of GWAS hits among non-binary trait 113 
   
 
   
 
Just below 5 million of the circa 1 billion tests performed across 118 non-binary 114 
traits were significant at a conventional genome wide threshold (P<10-8) 115 
(Supplementary Table 2), and 3,117,904 were significant after Bonferroni 116 
correction (P<0.05/9,113,133*118). The significant associations where 117 
distributed across 74,471 leading polymorphisms mapping to 38,651 118 
independent loci (Methods, Fig. 2, Supplementary Table 3). A substantial 119 
proportion of these associations (13.0%) were within the HLA region 120 
(Supplementary Table 2).  121 
 122 
About 9.5% of the tested polymorphisms reached genome-wide significant 123 
thresholds (P<10-8) for at least one of the 118 tested traits, whilst 82% of the 124 
tested polymorphisms were associated with at least one of these 118 traits at a 125 
significance level of 10-2 (Supplementary Table 4). There were 20,393 genetic 126 
variants each associated with more than 30 of the tested non-binary traits (Figs. 127 
2 and 3, Supplementary Fig. 1). A cluster of nine variants in a 9kb region including 128 
the genotyped intronic variant rs1421085 within the FTO gene had the largest 129 
number of genome-wide significant associations outside the HLA region, all nine 130 
variants being found to be associated with 58 traits (Fig. 3 and Supplementary 131 
Fig. 1). The genotyped variant rs1421085 at the FTO locus also had the largest 132 
average significance across non-binary traits (P<10-74) (Supplementary Fig. 2), 133 
which was largely contributed by the associations to anthropometric traits such 134 
as BMI and Weight which showed some of the strongest associations (P<10-300). 135 
The HLA region contained 362 genetic variants which were significantly (P<10-8) 136 
associated with 50 or more of the non-binary traits compared to only 128 such 137 
variants in the remaining autosomal variants. About 36% of the analyzed imputed 138 
HLA alleles were significant (P<10-8) for at least one trait (Supplementary Fig. 3). 139 
Six traits ('Standing height', 'Sitting height', 'Platelet count', 'Mean platelet 140 
(thrombocyte) volume', ’Trunk predicted mass’, ‘Trunk fat-free mass’) had over 141 
100,000 significant associations (P<10-8) each distributed across 25,352 different 142 
independent lead genetic variants (Methods). Over 94% of the non-binary traits 143 
had more than 100 genome-wide significant hits distributed in 74,442 different 144 
leading genetic variants.  145 
 146 
   
 
   
 
Considering the criteria for inclusion of genetic polymorphisms on the genotyping 147 
array (Supplementary Table 5), the HLA polymorphisms were the most enriched 148 
for associations with at least one non-binary trait (88% had a P<10-8), followed 149 
by the Cardiometabolic, Autoimmune/Inflammatory and ApoE criteria, whilst the 150 
lowest enrichment was for two low frequency variants categories (“Genome-wide 151 
coverage for low frequency variants” and “Rare, possibly disease causing, 152 
mutations”). Less than 8 in 100 of these polymorphisms were associated with any 153 
non-binary trait (Supplementary Table 5).  154 
 155 
We found a significant correlation (r=0.93, P<10-51) between the number of hits 156 
and the SNP heritability of the traits, suggesting that the number of loci affecting 157 
a trait might be proportional to the heritability of the trait (Fig. 4, Supplementary 158 
Fig. 4). Consistent with this model and variation in the distribution of linkage 159 
disequilibrium across the genome, the correlation of the SNP heritability with the 160 
number of identified independent lead variants was similarly high (r=0.88, P<10-161 
38). The number of hits (P<10-8) per chromosome was highly correlated (r=0.86) 162 
with the length of the chromosome covered by the genotyped SNPs 163 
(Supplementary Fig. 5, Supplementary Table 6). Although this correlation could 164 
arise under a polygenic model where the length of the chromosome is correlated 165 
with the number of possible variants affecting the traits, the simplest explanation 166 
is that it arises as a consequence of the correlation of chromosomal length and 167 
number of tested variants per chromosome. Comparing the fit of two nested 168 
models to explain the number of hits per chromosome as a function of number of 169 
tested genetic variants and length of the chromosome or just the number of 170 
genetic variants was consistent with the number of GWAS hits per chromosome 171 
correlating with the length of the chromosome rather than the number of tested 172 
variants (Methods). 173 
 174 
Standing height was the trait with the largest number of hits (Fig. 5) with 261,908 175 
significantly associated variants distributed across 10,374 independent lead 176 
variants. We estimated that the leading polymorphisms across the 118 traits 177 
studied are distributed among 38,651 independent loci, therefore 27% of these 178 
independent loci contribute to the variation of height, as expected by a highly 179 
polygenic trait7. We also computed the proportion of tested genetic variants 180 
   
 
   
 
associated with at least one disease (P < 10-8) that are also associated with height 181 
and BMI at different thresholds (Supplementary Table 7). At a threshold of 10-8, 182 
~28% and ~7% of the genetic variants associated for height and BMI, 183 
respectively, were also associated with at least one disease. This is important for 184 
the interpretation of Mendelian Randomisation studies as it is likely that one of 185 
the critical assumptions to demonstrate causality, that is, that there is no 186 
pleiotropy between the exposure and the outcome, may be broken for many 187 
exposure-outcome pairs. 188 
 189 
Distribution of GWAS hits among binary traits 190 
The binary trait with the largest number of cases was self-reported hypertension, 191 
with an average across binary traits of 6,593 cases (Supplementary Table 1). Of 192 
the 660 binary phenotypes 86 were specific to one sex (Supplementary Table 1). 193 
Individuals of the unaffected sex were excluded from the analysis for these 194 
phenotypes (Methods). Consistent with the reduced statistical power to detect 195 
association with binary phenotypes (mainly diseases) compared to non-binary 196 
traits we detected 393,023 associations at a P<10-8 (Supplementary Table 2), 197 
61% of those were within the HLA region. Similarly, almost half (i.e. 48%) of the 198 
analyzed imputed HLA alleles were significant (P<10-8) for at least one binary trait 199 
(Supplementary Fig. 3). Approximately 1 in 15,000 of the genotype-phenotype 200 
pairs was genome-wide significant (P<10-8) for binary traits, whilst approximately 201 
1 in 200 genotype-phenotype pairs were significant (P<10-8) for non-binary traits. 202 
Among the tested genetic variants, one in ~80 was associated with at least one 203 
binary trait, whilst one in ~10 was associated with one non-binary trait. Only 204 
genetic variants within the HLA region were associated with more than 20 binary 205 
traits each (Figs. 3, Supplementary Fig. 1 and 6). 206 
 207 
We found a positive correlation (r=0.64, P<10-76 in the observed scale, r=0.56, 208 
P<10-53 in the liability scale) between the heritability of the binary trait and the 209 
number of genome-wide significant variants, albeit of smaller magnitude to that 210 
found for the non-binary traits (Fig. 4). Some of these traits were obvious outliers 211 
as they had large heritabilities but few significantly associated variants. The three 212 
largest heritabilities for binary traits were for three autoimmune diseases 213 
   
 
   
 
(ankylosing spondylitis, coeliac disease and seropositive rheumatoid arthritis) but 214 
few significant variants were found outside the HLA region for these traits. For 215 
instance, 5,704 out of 5,706 genome-wide significant associations for ankylosing 216 
spondylitis were within the HLA region. 217 
 218 
Among the categories for inclusion of genetic variants in the genotyping array 219 
there was a substantial enrichment for HLA (79%), ApoE (48%), and Cancer 220 
common variants (40%). The categories with the lowest enrichment were 221 
genome-wide coverage for low frequency variants (0.15%) and tags for 222 
Neanderthal ancestry (0.8%) (Supplementary Table 5). 223 
 224 
We show three examples of Manhattan plots for binary traits (Fig. 5). The first 225 
example shows where there are associations with skin cancer (i.e melanoma and 226 
other malignant neoplasms of the skin). There are 4795 variants associated 227 
(P<10-8) with skin cancer distributed among 172 independent lead variants 228 
(Supplementary Table 3). We found associations in genetic variants in or around 229 
known susceptibility genes (e.g. MC1R, IRF4, TERT, TYR) for melanoma8, but 230 
also genes like FOXP1 (rs13316357, P=1.5x10-15) associated with basal cell 231 
carcinoma9. The other two examples show the similarity between the results of 232 
one of the self-reported and clinically defined traits available in UK Biobank. The 233 
Manhattan plots for self-reported and clinically defined coeliac disease are very 234 
similar but not identical, which suggests that generally there will be benefit in 235 
analyzing both clinically and self-reported traits. 236 
 237 
Heritability Estimates  238 
Heritability estimates inform about the contribution of genetics to the observed 239 
phenotypic variation. The heritability of many of the 778 traits analysed here has 240 
never been reported, but even if they have been reported it is useful to know how 241 
much phenotypic variation is captured by genetic variants in a cohort of the size 242 
and interest of UK Biobank. The majority (78%) of the traits analyzed had a 243 
significant SNP-heritability (P<0.05; Fig. 6), with the largest SNP-heritability being 244 
for ankylosing spondylitis, which was 0.86 on the liability scale. The mean and 245 
median heritability among those estimates that were significant were 0.12 and 246 
   
 
   
 
0.08, respectively. Mean heritabilities were significantly different for binary and 247 
non-binary traits (h2Non-binary=0.17; h2Binary=0.10; P=4x10-12). A total of thirty-six 248 
traits, all binary, had a heritability estimate close to zero (h2Liability < 10-4). Only 249 
seven of those thirty-six traits had no genome-wide significant hits (P<10-8), with 250 
nine having more than ten significant hits, self-reported gastritis having the largest 251 
number of hits with 41. This scenario could arise for monogenic and oligogenic 252 
traits for which the model assumptions do not hold or because of false positives. 253 
The Manhattan plots for the traits that had the largest numbers of hits seem more 254 
consistent with these hits being false positives or perhaps lack of power to detect 255 
heritability than with the violation of the model assumptions (Supplementary Fig. 256 
7). 257 
 258 
Estimates of genetic and environmental correlations show that for 15% of the 259 
pairs of non-binary traits the genetic and environmental correlation changes sign 260 
(Supplementary Fig. 8, GeneATLAS web page). Across all pairs of non-binary 261 
traits for which the genetic and environmental correlation had the same sign the 262 
absolute value of the genetic correlation was smaller in 31% of the cases. Overall, 263 
taking into account the size of observed heritabilities, this suggests that the 264 
phenotypic covariance of many of these traits is likely driven by the environment 265 
and not genetics (average (covg/cove)=0.24, among traits where covg and cove 266 
have the same sign). 267 
 268 
Phenotypic prediction from genetic markers 269 
We computed genomic predictions (that is, models of phenotypic prediction 270 
based on genetic markers) for all 692 non-gender dependent traits using 271 
Genomic Best Linear Predictions (GBLUP)10 (Methods). GBLUP estimates 272 
polygenic risk scores assuming that all fitted variants have an effect. It has been 273 
argued that this method has several advantages to traditional polygenetic risk 274 
scores from GWAS hits10,11. Some of the traits for which we developed GBLUP 275 
models did indeed reach large prediction accuracies (Fig. 7), which was further 276 
increased when we used additional covariates such as gender or sex. The largest 277 
prediction accuracy for a non-binary trait was for height which was 0.59, whilst 278 
the largest discriminative ability for a binary trait was 0.82 for self-reported 279 
   
 
   
 
malabsorption/coeliac disease. We observed a large correlation between the 280 
prediction accuracy and the trait heritability (Fig. 7 and Supplementary Table 8). 281 
Furthermore, we previously developed a model that predicted the benefit of 282 
having increasingly large training datasets for prediction of complex traits in UK 283 
Biobank11,12. Our current accuracy of prediction for anthropomorphic traits is very 284 
similar to the ones we previously predicted we would achieve with this training 285 
set11 (Supplementary Fig. 9). 286 
DISCUSION 287 
We used circa 452,000 related and unrelated UK Biobank participants of white 288 
ethnicity to build the largest atlas of genetic associations to date. Summary 289 
statistics for 778 traits will be available to the research community to help them 290 
gain further insight into the genetic architecture of complex traits. Unlike other 291 
currently available databases, like the GWAS catalog (which contains 292 
~39,366 unique SNP-trait associations), our database includes significant and 293 
non-significant associations, thus providing an unbiased view of phenotype-294 
genotype associations across a large number of traits within a single cohort. In 295 
addition, the database contains 182,266 independent genotype-phenotype 296 
associations, genetic and environmental correlations, and estimates of SNP 297 
heritability to allow researchers to perform their own filters on what a meaningful 298 
association or heritability is. We hope this database will be useful to those 299 
working on complex traits genetics, but also to those that have not got the 300 
expertise or capabilities to perform analyses at this scale.  301 
 302 
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Figures 374 
 375 
 376 
Figure 1: The effect of sample size on the number of GWAS hits and their 377 
estimated effects. (a) Comparison between the p-values (two-sided t-test) 378 
obtained using the whole cohort (452,264 individuals) and random subsamples 379 
of increasing sizes. The plot shows only the results for the genetic variants 380 
associated with a p-value < 10-8 in the whole cohort. (b) Total number of 381 
detected associated variants (two-sided t-test) at a threshold of p-value < 10-8 382 
as a function of the sample size. (c) Slope of the effect sizes of the GWAS hits 383 
obtained in random subsamples of increasing size vs the same effect sizes 384 
estimated in the whole cohort. Slopes larger than one indicate an inflation on 385 
the effect estimates in the smaller sample. The black line joints the mean at 386 
each sample size shown. Error bars indicate the standard deviation.  387 
 388 
 389 
 390 
  391 
   
 
   
 
Figure 2. Histograms of numbers of significant associations (two-sided t-392 
test, P < 10-8). The panels show results for each phenotype (left) and 393 
independent lead variant (right) for non-binary (top) and binary (bottom) 394 
phenotypes. 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
  408 
   
 
   
 
Figure 3. Number of significant associations (two-sided t-test, P < 10-8). 409 
The panels show the number of significant associations at each tested genetic 410 
variant for all traits, non-binary and binary phenotypes. The HLA region 411 
(±10Mb) is indicated.        412 
 413 
 414 
 415 
  416 
   
 
   
 
Figure 4. Relationship between estimated SNP heritability and numbers 417 
of genome wide significant associations (two-sided t-test, P < 10-8). HLA 418 
and surrounding 10Mb region were excluded for non-binary and binary 419 
phenotypes respectively. 420 
  421 
 422 
 423 
 424 
  425 
   
 
   
 
Figure 5. Manhattan plots for selected phenotypes. Manhattan plots for the 426 
phenotypes with the largest number of genome wide significant associations 427 
(two-sided t-test, P < 10-8) within each of these categories: non-binary 428 
phenotypes, cancer registry, self-reported non-cancer illness, clinically defined 429 
disease from hospital episode statistics and matching self-reported disease to 430 
the clinically defined disease from hospital episode statistics. From top to 431 
bottom: non-binary phenotypes (Standing height), cancer registry (Melanoma 432 
and other malignant neoplasms of skin), self-reported non-cancer illness 433 
(hypertension), clinically defined malabsorption, and self-reported 434 
malabsorption. Genetic variants with P < 10-30 are indicated by marks along the 435 
top of each plot.  436 
   
 
   
 
 437 
Figure 6. Numbers of phenotypes of different SNP heritability. Colours 438 
indicate the fraction of phenotypes with heritability significantly (P < 0.05, Chi-439 
squared test, see Online Methods for details) different from zero in each bin.  440 
 441 
 442 
 443 
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 449 
 450 
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 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
Figure 7. Phenotypic prediction accuracy from genetic markers. Accuracy 465 
of phenotypic prediction as a function of the estimated SNP-heritability for (a) 466 
non-binary traits and (b) binary traits when no covariates were used for 467 
prediction. Comparison between prediction accuracy when covariates are 468 
included or not included for (c) non-binary traits and (d) binary traits. 469 
 470 
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ONLINE METHODS  473 
Phenotypes  474 
In total we analysed 778 phenotypes in UK Biobank participants of white 475 
ethnicity. These included 657 binary phenotypes generated from self-reported 476 
disease status (UK Biobank field 20002), ICD10 codes from hospitalization 477 
events (UK Biobank fields 41202 and 41204), and ICD10 codes from cancer 478 
registries (UK Biobank fields 40006), as well as a further 3 binary and 118 non-479 
binary (comprising continuous and ordered integral measures) phenotypes 480 
from across the UK Biobank. Amongst the 660 binary phenotypes 86 exhibited 481 
either a complete lack of cases in one sex or a strong imbalance in prevalence 482 
in the two sexes, i.e, the ratio between the smaller and larger prevalence was 483 
<0.02. Of these 86 phenotypes 72 where specific to women. We only included 484 
individuals of the appropriate sex, i.e., the sex with higher prevalence, in the 485 
analysis of these sex specific phenotypes. A description of each phenotype, its 486 
category and the relevant UK Biobank fields can be found in Supplementary 487 
Table 1 and Gene ATLAS website. The non-binary phenotypes were not scale 488 
transformed, so the units of the effect sizes are in the units reported in the UK 489 
Biobank database. The phenotypes for individuals with negative coding were 490 
replaced with the corresponding value (Supplementary Table 9). We also 491 
ordered the keys for the ordinal phenotypes with unordered keys in the UK 492 
Biobank database (Supplementary Table 10). The individuals with a phenotype 493 
departing 10 standard deviations from their gender mean were set as missing 494 
for traits with a value type defined as “Integer” or “Continuous” by UK Biobank. 495 
The exceptions to this were Number of self-reported cancers (134-0.0), Number 496 
of self-reported non-cancer illnesses (135-0.0), Nucleated red blood cell 497 
percentage (30230-0.0), Nucleated red blood cell count (30170-0.0), and 498 
Frequency of solarium/sunlamp use (2277-0.0) which were left as reported by 499 
UK Biobank. Some of the traits analysed have some redundancy that has been 500 
left for completeness. That is, some of these traits were measured in different 501 
ways during the study (e.g. weight) or are analysed as self-reported traits and 502 
clinical traits (e.g. malabsorption). For disease traits all individuals reporting a 503 
disease code were coded as cases with all other individuals considered 504 
controls. Only non-disease phenotypes with missing data rate < 5% were 505 
   
 
   
 
selected for analysis. For these phenotypes missing values were imputed to 506 
the age and sex specific mean in the study cohort.  507 
 508 
Analysis Checks 509 
Extensive validation steps were performed to ensure the reliability of the data 510 
(Supplementary Material). These steps included, for instance, a comparison of 511 
effect sizes with previous results from GWAS published in GWAS Catalog 512 
(Supplementary Figs. 10-18), the investigation of how the polygenicity of the 513 
traits drive inflation factors in GWAS (Supplementary Fig. 19), and comparisons 514 
with repeated analyses where the non-binary phenotypes containing at least 515 
500 different values were transformed using a rank-based normal 516 
transformation (Supplementary Note, Supplementary Table 11, and 517 
Supplementary Fig. 20). The results are in good agreement. Since the 518 
statistical power may be different in some cases, the results are available at the 519 
GeneATLAS web. Furthermore, the comparison between our heritability 520 
estimations with previously published heritabilities showed a good agreement 521 
(Supplementary Fig. 21 and Supplementary Table 12) when comparing ten 522 
traits. In addition, we computed the Q-Q plots (Supplementary Fig. 22, and 523 
summary plots in GeneATLAS website). We also checked whether there were 524 
any areas depleted of associations, that is, that showed few significant 525 
associations (Supplementary Fig. 23 and 24).  Finally, we compared the 526 
coherence of the effect size directions estimated with the whole cohort and 527 
subsets of it of different sizes (Supplementary Table 13). 528 
 529 
Genotypes 530 
The genotypes of the UK Biobank participants were assayed using either of two 531 
genotyping arrays, the Affymetrix UK BiLEVE Axiom or Affymetrix UK Biobank 532 
Axiom array. These arrays were augmented by imputation of ~90 million 533 
genetic variants from the Haplotype Reference Consortium5, the thousand 534 
genomes13 and the UK 10K13 projects. Full details regarding these data have 535 
been published elsewhere14.  536 
 537 
We excluded individuals who were identified by the UK Biobank as outliers 538 
based on either genotyping missingness rate or heterogeneity, whose sex 539 
   
 
   
 
inferred from the genotypes did not match their self-reported sex and who were 540 
not of white ancestry (based on both, self-reported ethnicity and those from 541 
whom one of the two first genomic principal components did not fall within 5 542 
standard deviations from the mean). Finally, we removed individuals with a 543 
missingness >5% across variants which passed our quality control procedure 544 
and those that have a missing phenotype for 40 or more traits. The resulting 545 
study cohort comprised 452,264 individuals.  546 
 547 
From the genotyped data we only retained bi-allelic autosomal variants which 548 
were assayed by both genotyping arrays employed by UK Biobank. We 549 
furthermore excluded variants which had failed UK Biobank quality control 550 
procedures in any of the genotyping batches. Additionally, for imputed and 551 
genotyped variants, we excluded variants with P < 10-50 for departure from 552 
Hardy-Weinberg, computed on a subset of 344,057 unrelated (Kinship 553 
coefficient < 0.0442) individuals in the White-British subset of the study cohort, 554 
and with a missingness rate > 2% in the study cohort. Although we analysed all 555 
imputed variants and all genotyped variants with MAF > 10-4 (all results 556 
available on the GeneATLAS website), only imputed variants with MAF>10-3 in 557 
the study cohort and imputation score larger than 0.9 were used for the 558 
summary results presented here. This cut-off corresponds to less than 905 559 
occurrences of the minor allele in the study cohort. We also filtered the HLA 560 
imputed alleles that were present in fewer than 10 individuals. 561 
 562 
GWAS Analysis 563 
To test each genetic variant whilst taking into account population structure in 564 
UK Biobank (e.g. presence of related individuals or local structure), we used a 565 
Linear Mixed Model. Specifically, the model takes the form 566 
𝐲 = 𝐗𝛃 + 𝐠 + 𝛜, 567 
where y is the vector of phenotypes, X, is the matrix of fixed effects, and  the 568 
effect size of these effects. We included as fixed effects sex, array batch, UK 569 
Biobank Assessment Center, age, age2, and the leading 20 genomic principal 570 
components as computed by UK Biobank. g is the polygenic effect that 571 
captures the population structure, fitted as a random effect. It follows the 572 
   
 
   
 
distribution 𝐠~𝐍(0, 𝐀𝜎𝑔
2), with A the Genomic Relationship Matrix (GRM), and 573 
𝜎𝑔
2 the variance explained by the additive genetic effects. The GRM was 574 
computed using common (MAF > 5%) genotyped variants that passed quality 575 
control. Finally, 𝛜~𝐍(0, 𝐈𝜎𝜖
2) is a residual effect not accounted for by the fixed 576 
and random effects. Under this model, the phenotype vector 𝐲, follows the 577 
distribution 𝐍(𝐗𝛃, 𝐀𝜎𝑔
2 + 𝐈𝜎𝜖
2). 578 
 579 
Fitting one instance of such a LMM model is computationally very demanding. 580 
Following a naïve approach, the required computational time increasing with 581 
the cube of the sample size, ~O(N3), and the memory requirements with the 582 
square of the sample size, ~O(N2). Consequently, fitting a single model on a 583 
cohort of the size of UK Biobank is challenging, and fitting millions of these 584 
models, one for each analysed genetic variant and phenotype is not feasible 585 
with standard computational and statistical approaches. To address this 586 
problem, we took advantage of three different tools. First, we used a large 587 
supercomputer, and DISSECT3 to speed up the calculations (e.g. computing 588 
the GRM eigen-decomposition required 5,040 processor cores working 589 
together for ~10h, and using ~5TB of memory). Second, we computed the full 590 
eigen decomposition of the GRM, 𝐀 = 𝚲𝚺𝚲𝑇, where 𝚲 is the matrix of 591 
eigenvectors, and 𝚺 is a diagonal matrix containing the eigenvalues. This 592 
allowed us to transform all the other model matrices, y, X, and 𝛜 to the new 593 
space where the GRM is diagonal. Although the eigen-decomposition is a 594 
computationally intensive process, once diagonalized, the computational time 595 
of fitting a model is reduced considerably to ~O(N), thus enabling us to perform 596 
several tests using Mixed Linear Models on a cohort of hundreds of thousands 597 
of individuals. Finally we performed over 23 billion tests using a two-step 598 
approximation that optimizes the computational resources15. The first step of 599 
the approximation fits a LMM that adjusts by the relevant fix (e.g. age, sex, etc.) 600 
and random effects (genetic effects) to each trait, the second step uses the 601 
residuals of LMM to test (two-tailed t-test on effect sizes) all available genetic 602 
markers for significance in a linear model. We corrected for the polygenic effect 603 
using a Leave-One-Chromosome-Out (LOCO) approach16.  604 
 605 
   
 
   
 
HLA Region  606 
We defined the HLA region as the region of chromosome 6 spanning base pairs 607 
28,866,528 to 33,775,446. Throughout all analyses we included 10Mb either 608 
side of the above HLA region to account for LD with variants outside this region. 609 
The imputed HLA alleles were tested using the same GWAS model described 610 
above, where the independent variable is the best guess allele reported dosage 611 
from the HLA imputed values (UK Biobank field 22182). We tested the alleles 612 
using two models. A model where the number of copies of each HLA allele for 613 
each locus was tested independently as a fixed effect, and a second model 614 
where the number of copies of all alleles in a given locus were tested together 615 
as fixed effects in the same model (i.e. an omnibus test)17.  616 
 617 
Estimation of Genetic Parameters 618 
In order to estimate heritabilities and genetic correlations we fitted LMMs for 619 
each trait with a GRM containing all common (MAF > 5%) autosomal genetic 620 
variants which passed QC. The heritability was estimated as ℎ𝑔
2 =621 
𝜎𝑔
2/(𝜎𝑔
2 + 𝜎𝜖
2), where 𝜎𝑔
2 and 𝜎𝑒
2 are the estimates of the genetic and residual 622 
variance and the p-values were obtained using a Chi-squared test following the 623 
method described previously18,19. For all binary outcomes, we transformed 624 
heritabilities on the observed scaled to the liability scale using the population 625 
prevalence of the disease. We provide sex-specific prevalences to allow sex-626 
specific transformations (Supplementary Table 1). Using the model fits we 627 
computed best linear unbiased predictor estimates of genetic additive values 628 
for each individual. The genetic correlations were estimated by computing 629 
correlations between these additive genetic values. Environmental correlations 630 
were estimated as 𝑟𝑒 = (𝑟𝑦 − √ℎ𝑖
2ℎ𝑗
2 𝑟𝑔)/√(1 − ℎ𝑖
2)(1 − ℎ𝑗
2), where 𝑟𝑦, 𝑟𝑔 are the 631 
phenotypic and genetic correlations for traits 𝑖 and 𝑗. 632 
  633 
Lead variants and Independent Loci 634 
We clustered GWAS results into independent lead variants using the --clump 635 
option of the PLINK 1.9 software20,21. Specifically, for each trait individually, we 636 
clustered GWAS results by selecting genome wide significant variants as lead 637 
variants and assigning to them unassigned variants within 10Mb, that have 638 
   
 
   
 
P<10-2 and a 𝑟2 > 0.3 with the lead variant. To compute the total number of 639 
independent loci across all traits, we performed the same clustering on the lead 640 
variants across all traits, choosing the lowest p-value for variants which were 641 
lead variants in different traits.     642 
 643 
Relation of number of associations and chromosome length  644 
We regressed the number of significant associations (P<10-8) across traits for 645 
each chromosome on the covered length of the chromosome, i.e., distance in 646 
base pairs of the first and last tested genetic variants, and the number of genetic 647 
variants tested on the chromosome. For chromosome 6 we excluded the HLA 648 
region and variants contained therein from the statistics. We compared the full 649 
model to one with either the chromosomal length or number of tested genetic 650 
variants removed using the likelihood ratio test. The full model was not 651 
significantly better than the model containing only chromosomal length 652 
(P=0.08) but was significantly better than the model containing only the number 653 
of genetic variants (P=0.004). Both reduced models were significant when 654 
compared to a null model containing only an intercept. 655 
 656 
 657 
Phenotypic prediction 658 
The effect of all common genetic variants (MAF>0.05) were estimated together 659 
as a random effect using the model, 660 
𝑦𝑖 = 𝜇 + ∑ 𝑥𝑖𝑙𝛽𝑙
𝐿
𝑙=1
+ ∑ 𝑧𝑖𝑗𝑎𝑗
𝑀
𝑗=1
+ 𝑒𝑖, 661 
where 𝜇 is the mean term and 𝑒𝑖 the residual for individual 𝑖. 𝐿 is the number of 662 
fixed effects, 𝑥𝑖𝑙 being the value for the fixed effect 𝑙 at individual 𝑖 and 𝛽𝑙 the 663 
estimated effect of the fixed effect 𝑙 . We fitted the same covariates as in the 664 
GWAS analyses. 𝑀 is the number of markers and 𝑧𝑖𝑗 is the standardised 665 
genotype of individual 𝑖 at marker 𝑗. The vector of effects of random common 666 
genetic variants 𝐚 is distributed as N(0, 𝐈𝜎𝑢
2). The vector of environmental 667 
   
 
   
 
effects 𝐞 is distributed as N(0, 𝐈𝜎𝑒
2). Defining 𝜎𝑔
2 = 𝑀𝜎𝑢
2, the heritabilities were 668 
estimated as 𝜎𝑔
2/(𝜎𝑒
2 + 𝜎𝑔
2). 669 
The prediction of the phenotype 𝑦?̂? for the individual 𝑖 was computed as a sum 670 
of the product of the SNP effects and the number of reference alleles of the 671 
corresponding SNPs: 672 
𝑦?̂? = ∑
(𝑠𝑖𝑗 − 𝜇𝑗
∗)
𝜎𝑗
∗ 𝑎𝑗
𝑀
𝑗=1
, 673 
where 𝑠𝑖𝑗 is the number of copies of the reference allele at marker 𝑗 of individual 674 
𝑖, 𝑀 is the number of markers used for the prediction, and 𝑎𝑗 the effect of marker 675 
𝑗. 𝜇𝑗
∗ and 𝜎𝑗
∗ are the mean and the standard deviation of the effect allele in the 676 
training population. 677 
We used 407,669 genetically confirmed white British to train the models and 678 
44,595 whites of non-British descent to validate the models. We restricted this 679 
analysis to the 692 non-gender specific phenotypes. Prediction accuracies for 680 
non-binary traits were computed as the Spearman correlation between the 681 
predicted and the real phenotype of white participants of non-British descent 682 
after correcting by the estimated effect of the used covariates. Prediction 683 
accuracies for binary traits were computed as the Area Under the Curve (AUC) 684 
of a Receiver Operating Characteristic (ROC) curve using the predicted and 685 
the real phenotypes of white individuals of non-British descent.  686 
 687 
Reporting Summary 688 
Further information on experimental design is available in the Life Sciences 689 
Reporting Summary linked to this article. 690 
 691 
   
 
   
 
Code availability 692 
The source code of DISSECT, the tool used for GWAS and heritability 693 
estimations, is freely available at https://www.dissect.ed.ac.uk under GNU Lesser 694 
General Public License v3. 695 
 696 
Data availability 697 
All summary results from the analyses performed are available at GeneATLAS 698 
website, http://geneatlas.roslin.ed.ac.uk/. 699 
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